Industry Reports

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a wide range of tumors; Anti-CD39 broadens Innate Pharma’s portfolio of innovative immuno-oncology...

CTI BioPharma Corp. announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds...

Seattle Genetics and Bristol-Myers Squibb (BMS) have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Adcetris and Opdivo in two planned Phase I/II clinical trials. Adcetris (brentuximab vedotin) is Seattle Genetics'...

Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn. As part of the deal, Shire will acquire NPS Pharma's outstanding shares for $46 per share in cash. The transaction was...

US-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for $635m. As part of the deal, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines...

US-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical stage biopharmaceutical company, AliosBioPharma, for $1.75bn in cash. Based in California, US, AliosBioPharma develops therapies for the treatment of viral diseases. The...

Aegerion Pharmaceuticals has signed an agreement to acquire an orphan product Myalept (metreleptin for injection) from AstraZeneca. AstraZeneca will receive $325m upfront payment to divest the rights to develop, manufacture and commercialise Myalept, subject to an...